See more : Jyske Bank A/S (JYSK.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Prothena Corporation plc (PRTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Prothena Corporation plc, a leading company in the Biotechnology industry within the Healthcare sector.
- OreCorp Limited (ORR.AX) Income Statement Analysis – Financial Results
- KB Financial Group Inc. (KB) Income Statement Analysis – Financial Results
- Advanced Emissions Solutions, Inc. (ADES) Income Statement Analysis – Financial Results
- Public Power Corporation S.A. (PUPOF) Income Statement Analysis – Financial Results
- Surgutneftegas Public Joint Stock Company (SGGD.L) Income Statement Analysis – Financial Results
Prothena Corporation plc (PRTA)
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 91.37M | 53.91M | 200.58M | 853.00K | 814.00K | 955.00K | 27.52M | 1.06M | 1.61M | 50.85M | 676.00K | 2.66M | 507.00K | 1.24M |
Cost of Revenue | 220.57M | 6.74M | 82.28M | 74.88M | 50.84M | 101.18M | 134.55M | 119.53M | 58.44M | 38.45M | 26.05M | 34.14M | 0.00 | 0.00 |
Gross Profit | -129.20M | 47.16M | 118.29M | -74.03M | -50.02M | -100.23M | -107.03M | -118.48M | -56.83M | 12.40M | -25.38M | -31.48M | 507.00K | 1.24M |
Gross Profit Ratio | -141.40% | 87.49% | 58.98% | -8,678.90% | -6,145.21% | -10,495.08% | -388.92% | -11,230.24% | -3,536.53% | 24.39% | -3,753.85% | -1,184.39% | 100.00% | 100.00% |
Research & Development | 220.57M | 135.56M | 82.28M | 74.88M | 50.84M | 101.18M | 134.55M | 119.53M | 58.44M | 38.45M | 26.05M | 34.14M | 24.17M | 9.79M |
General & Administrative | 61.84M | 49.90M | 46.32M | 38.70M | 35.74M | 42.48M | 48.23M | 41.06M | 23.11M | 19.05M | 15.05M | 9.93M | 5.58M | 3.62M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 61.84M | 49.90M | 46.32M | 38.70M | 35.74M | 42.48M | 48.23M | 41.06M | 23.11M | 19.05M | 15.05M | 9.93M | 5.58M | 3.62M |
Other Expenses | 0.00 | 5.95M | -54.00K | 1.31M | 8.40M | 2.74M | -2.35M | 571.00K | 26.00K | 310.00K | -225.00K | 0.00 | 0.00 | 0.00 |
Operating Expenses | 282.41M | 185.46M | 128.60M | 113.59M | 86.57M | 143.67M | 182.77M | 160.59M | 81.54M | 57.50M | 41.10M | 44.07M | 29.75M | 13.41M |
Cost & Expenses | 282.41M | 185.46M | 128.60M | 113.59M | 86.57M | 143.67M | 182.77M | 160.59M | 81.54M | 57.50M | 41.10M | 44.07M | 29.75M | 13.41M |
Interest Income | 31.01M | 6.35M | 42.00K | 1.37M | 8.20M | 6.39M | 3.55M | 0.00 | 196.00K | 79.00K | 71.00K | 5.00K | 0.00 | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 8.20M | 3.70M | 3.69M | 0.00 | 0.00 | 0.00 | 154.00K | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 928.00K | 6.74M | 6.80M | 6.98M | 6.82M | 3.22M | 3.07M | 2.43M | 806.00K | 743.00K | 660.00K | 468.00K | 391.00K | 191.00K |
EBITDA | -190.11M | -131.56M | 71.98M | -111.22M | -78.94M | -152.90M | -152.19M | -156.54M | -79.13M | -5.91M | -39.77M | -40.94M | -28.85M | -11.97M |
EBITDA Ratio | -208.06% | -244.05% | 35.88% | -13,216.18% | -10,542.87% | -13,252.88% | -564.17% | -15,121.80% | -4,974.30% | -13.07% | -5,980.33% | -1,557.94% | -5,690.93% | -963.07% |
Operating Income | -191.04M | -131.56M | 71.98M | -112.73M | -85.70M | -158.86M | -155.25M | -159.54M | -79.94M | -6.65M | -40.43M | -41.41M | -29.24M | -12.16M |
Operating Income Ratio | -209.08% | -244.05% | 35.88% | -13,216.18% | -10,527.89% | -16,634.03% | -564.17% | -15,121.80% | -4,974.30% | -13.07% | -5,980.33% | -1,557.94% | -5,768.05% | -978.44% |
Total Other Income/Expenses | 30.56M | 5.95M | -54.00K | 1.31M | 8.40M | 2.74M | -2.35M | 571.00K | 26.00K | 310.00K | -154.00K | 5.00K | 0.00 | 0.00 |
Income Before Tax | -160.48M | -125.61M | 71.92M | -111.43M | -77.30M | -156.12M | -157.60M | -158.96M | -79.91M | -6.34M | -40.58M | -41.41M | -29.24M | -12.16M |
Income Before Tax Ratio | -175.64% | -233.01% | 35.86% | -13,062.95% | -9,496.07% | -16,347.12% | -572.71% | -15,067.68% | -4,972.68% | -12.47% | -6,003.11% | -1,557.75% | -5,768.05% | -978.44% |
Income Tax Expense | -13.45M | -8.66M | 4.95M | -283.00K | 379.00K | -470.00K | -4.37M | 1.14M | 701.00K | 811.00K | 415.00K | 6.00K | 426.00K | 320.00K |
Net Income | -147.03M | -116.95M | 66.98M | -111.14M | -77.68M | -155.65M | -153.24M | -160.11M | -80.61M | -7.15M | -41.00M | -41.41M | -29.67M | -12.48M |
Net Income Ratio | -160.91% | -216.95% | 33.39% | -13,029.78% | -9,542.63% | -16,297.91% | -556.84% | -15,176.11% | -5,016.30% | -14.06% | -6,064.50% | -1,557.98% | -5,852.07% | -1,004.18% |
EPS | -2.76 | -2.47 | 1.51 | -2.78 | -1.95 | -3.93 | -4.07 | -4.66 | -2.66 | -0.29 | -2.20 | -2.84 | -1.68 | -0.71 |
EPS Diluted | -2.76 | -2.47 | 1.38 | -2.78 | -1.95 | -3.93 | -4.07 | -4.66 | -2.66 | -0.29 | -2.20 | -2.84 | -1.68 | -0.71 |
Weighted Avg Shares Out | 53.22M | 47.37M | 44.23M | 39.92M | 39.88M | 39.56M | 37.65M | 34.35M | 30.33M | 24.67M | 18.62M | 14.59M | 17.68M | 17.68M |
Weighted Avg Shares Out (Dil) | 53.22M | 47.37M | 48.46M | 39.92M | 39.88M | 39.56M | 37.65M | 34.35M | 30.33M | 24.67M | 18.62M | 14.59M | 17.68M | 17.68M |
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus
Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
Prothena to Report Third Quarter 2024 Financial Results on November 12
Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock?
Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength?
Prothena Announces Leadership Team Updates
What Makes Prothena (PRTA) a New Buy Stock
Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues
Prothena (PRTA) Q2 Earnings and Revenues Beat Estimates
Source: https://incomestatements.info
Category: Stock Reports